We are Hysensbio, a global dental therapeutics company. Introducing our regenerative patented peptide treating dental sensitivity, caries and periodontal diseases. We provide the path to healthy aging by aiding the completing of cell activation platform. Based on cell reactivation, the company developed a new peptide derived from CPNE7 protein, named Selcopintide that activates various dental cells to restore physiological dentin, periodontal ligament, and cementum. The peptide showed promising results in phase 1/2a clinical study. Currently, we are conducting phase 2 clinical trial in Korea and the US. HysensBio is providing a solution to common, lifetime dental problems using regenerative technology, ultimately helping people extend the longevity of their natural teeth.